194774Independent Medical College, Faisalabad, Pakistan.
172462Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221114862. doi: 10.1177/10760296221114862.
This systematic review aims to analyze the systemic administration of antifibrinolytics (tranexamic acid and aminocaproic acid) to prevent postoperative bleeding in patients with hemophilia.
This systematic review was conducted adhering to PRISMA guidelines. Only randomized controlled trials that assessed human subjects of any age or gender with any severity of hemophilia undergoing dental extractions, and systemically administered antifibrinolytic therapy compared to placebo were included. Post-operative bleeding episodes and adverse events were presented. PubMed, Cochrane, Embase, CINAHL, Web of Science, and Scopus were searched through April 15, 2022. The risk ratio (RR) and odds ratio (OR) applying 95% confidence intervals (CI) were computed using RevMan 5.4.1 (Cochrane).
Two randomized, placebo-controlled trials pooling in a total of 59 patients were pooled in this analysis. Among patients administered antifibrinolytic therapy, 84% reduced risk of post-operative bleeding was reported (RR = 0.16, 95% CI = 0.05-0.47, P = 0.0009). The chances of post-operative bleeding were reduced by 95% among the antifibrotics group (OR = 0.05, 95% CI = 0.01-0.22, P < 0.0001).
This review finds favorable outcomes for the routine use of antifibrinolytic therapy for dental extractions in hemophiliacs. Further trials are required to rationalize existing evidence.
本系统评价旨在分析抗纤维蛋白溶解剂(氨甲环酸和氨基己酸)全身给药预防血友病患者术后出血的效果。
本系统评价遵循 PRISMA 指南进行。仅纳入评估任何年龄、性别和任何严重程度的血友病患者行拔牙术,并接受抗纤维蛋白溶解治疗与安慰剂比较的随机对照试验。报告术后出血事件和不良事件。检索时间截至 2022 年 4 月 15 日,检索数据库包括 PubMed、Cochrane、Embase、CINAHL、Web of Science 和 Scopus。使用 RevMan 5.4.1(Cochrane)计算风险比(RR)和比值比(OR)及其 95%置信区间(CI)。
本分析纳入了两项共 59 例患者的随机、安慰剂对照试验。接受抗纤维蛋白溶解治疗的患者中,84%报告术后出血风险降低(RR=0.16,95%CI=0.05-0.47,P=0.0009)。抗纤维蛋白溶解剂组术后出血的可能性降低了 95%(OR=0.05,95%CI=0.01-0.22,P<0.0001)。
本综述发现抗纤维蛋白溶解治疗在血友病患者拔牙术中常规应用的结果有利。需要进一步的试验来合理化现有证据。